Austin, TX – September 20, 2022 – Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell’s management team, bringing industry-leading leadership to support the company’s clinical R&D strategy and operations.

Austin, TX – April 22, 2022 – Maxwell Biosciences today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately. Dr. Rudnic brings more than 30 years of diverse experience in the biosciences industry.

Austin, TX – March 10, 2022 – Maxwell has developed a groundbreaking drug platform technology with the potential to profoundly impact global health. This funding will accelerate our efforts to develop a new class of drugs designed to fight viruses and other pathogens.